Flashcards
Stroke and TIA

Cards in this deck (37)
- 1COW visual

- 2NICS TIA and CVA bundleRapid initial stroke screen
ABCD2 if TIA suspected
Urgent CT / MRI
NBM until bedside swallow screen
Aspirin if haemorrhage excluded
Monitoring and neuro obs - 3ABCD2Age > 60 = 1
BP > 140/90 = 1
Clinical features:
- unilateral weakness = 2
- speech impairment w/out weakness = 1
Duration of symptoms:
> 1 hr = 2
- 10-59 min = 1
DM = 1 - 4Scoring ABCD26 or 7 (high risk) - 2-day stroke risk 8%
- 7 day stroke risk 25 - 30%
4 or 5 (mod risk) - 2-day stroke risk 4%
- 7 day stroke risk 20-25%
0-3 (low risk) - 2-day stroke risk 1%
- 7 day stroke risk 0-15%
NICS dichotomises to high/low risk
- score > 4 = high risk
- score < 4 = low risk - 5Antiplatelet in CVAAspirin only proven antiplatelet for CVA
- CAST and IST trials confirm this
150 mg/day reduces risk of CVA by 20-30%
- 50% benefit occurs in first 2/52
Rx 1,000 AF pts with aspirin prevents 15 CVA per year
Clopidogrel and aspirin/dipyridamole
- may be more effective than aspirin alone
- may reduce risk of vascular events in AF - 6Anticoagulation in AFWarfarin reduces stroke in AF by 2/3
Based on risks of embolism and bleeding
Rx 1,000 AF pts prevents 30 CVAs, causes at least 2 major haemorrhage/yr
Aspirin if warfarin CI if no renal failure - 7MCA syndrome ?embolic or thromboticUsually embolic
- 8Common features MCA syndromeContralateral
- hemiplegia
- hemisensory loss
- homonymous hemianopia
Eyes deviated to side of lesion
Face and arm weakness > leg
Distal occlusion leads to more limited signs - 9ACA syndromeParalysis of contralateral leg and foot
Confusion
Abulia - diminished motivation
Grasp reflex present
Behavioural disturbance
Urinary incontinence - 10PCA syndromeHemianopia
Quadrantanopias
Cortical blindness
Memory loss
Dyslexia
Hemisensory loss
Ipsilateral III palsy - 11Vertebrobasilar infarctionCerebellar and brain stem lesions:
Ataxia
Dizziness
N/V
Nystagmus
Wide variety of CN palsies
Internuclear ophthalmoplegia - 12Internuclear ophthalmoplegiaEye fails to adduct
Lesion in medial longitudinal faciculus - 13Lateral medullary syndromeIpsilateral:
- UMN VIIth, IXth and Xth
- Horner’s
Contralateral spinothalamic loss (pain and temperature)
Conjugate gaze palsy - 14Wallenburg's syndromePosterior inferior cerebellar artery disease
Cerebellar signs
Dysphagia
Loss of pain and temp sensation
Weakness and paralysis - 15ROSIERGCS
BP
BSL - if <3.5 reassess
LOC or syncope? -1
Seizure? -1
New asymmetrical facial weakness? 1
New asymmetrical arm weakness? 1
New asymmetrical leg weakness? 1
Speech disturbance? 1
Visual field defect? 1 - 16ROSIER scores<=0 Stroke unlikely but not completely excluded
Designed to exclude stroke mimics - 17FASTFace Arm Speech Test
- 18NIH stroke scaleUsed in various stroke trials
Modified and simplified for ED use as Cincinnati prehospital stroke scale
Rapid and reproducible
Measures impairment caused by stroke
Allows comparison of deficit over time - 19CT for infarctionUsually no abnormality in first few hrs
- sens 50% within 6 hrs
- spec > 95%
Early changes usually indicate major infarction - 20Features of infarction on CTHELLO LP
Hyperdense MCA or other cerebral artery
- 100% specific, 50% sensitive for MCA occlusion
Effacement of cortical sulci
Local mass effect
Loss of insular ribbon
Obscuration of lentiform nucleus
Parenchymal hypodensity
Loss of grey/white differentiation - 21BP control in haemorrhagic strokeMay reduce haematoma volume
ICH ?less ischaemic penumbra than thrombotic, so hazards reduced
If sBP 200 or MAP 150, consider aggressive reduction
If sBP 180 or MAP 130 and ICP up, consider monitoring ICP and reducing BP while maintaining CPP > 60 mmHg
If ICP not up, consider reducing BP to MAP 110 or < 160/90
High risk for haematoma growth: SBP 140 - 22Efficacy of HASU46/1,000 patients spared death or dependency by stroke unit care
- 23Primary ICH managementCerebellar > 3 cm should go to OT
For non - cerebellar haemorrhages:
- surgery not commonly employed
- trial results do not support
Blood in ventricles associated with high mortality
- may be related to obstructive hydrocephalus
- drainage of CSF through ventricular catheters reduces ICP, but frequently clots - 24Modified Rankin0 No symptoms
1 No significant disability despite symptoms; able to carry out ADLs
2 Slight disability; unable to carry out all ADL, but independent
3 Mod disability; requiring help, but able to walk without assistance
4 Mod severe disability; unable to walk/ADLs without assistance
5 Severe; bedridden, incontinent and requiring constant nursing care
6 Dead - 25% of strokes that are ICH10-15%
- 26Primary haemorrhage80-90%
Spontaneous rupture of small vessels damaged by hypertension or amyloid
Charcout-Bouchard micro-aneurysms of penetrating arteries of
- MCA
- basilar
- Circle of Willis - 27Secondary HaemorrhageMinority with vascular abnormalities eg, AVMs, aneurysms
Haemorrhagic transformation assoc with:
tPA (greatest RF)
Cardioembolic strokes
ICA occlusion
Clopidogrel and aspirin
Anticoagulation
Hypertension
Hyperglycaemia - 28Thalamic haemorrhage clinical featuresContralateral hemiplegia
Eyes down and in
Unequal pupils
Absent light reflexes
Ipsilateral Horner’s
Lateral gaze defects
Prominent sensory deficit
Aphasia - 29Pontine haemorrhage clinical featuresDeep coma with quadriplegia
Pin point pupils
Decerebrate rigidity
Hyperpnoea
Hypertension
Hyperhydrosis - 30Commonest site of primary haemorrhagePutaminal
Eyes deviate to contralateral side
Contralateral hemiplegia - 31Key issues in the tPA debateValidity of key study results
Accurate representation of data and selective reporting of results
Role of industry in research
Level of evidence required to institute significant practice change
Allocation of resources between acute stroke care and other care - 32Dosing tPA (alteplase) for strokeCommenced within 3 hrs of onset:
0.9 mg/kg (90 mg max)
10% bolus
90% over 60 min - 33Summary of tPA (alteplase) trials12 trials published on thrombolysis (mostly alteplase)
2 RCTs found a benefit as defined by primary outcome measures (NINDS, ECASS-3)
2 were stopped early because of harm (ATLANTIS)
8 remaining studies had negative findings for primary outcome (IST-3 had a positive secondary outcome)
Supported by meta-analysis based on the above studies
Supported by large industry funded registry data-sets - 34Problems with trialsMissing data from studies stopped early
Heterogeneity calculations strongly suggest data pooling inappropriate
Imbalances in baseline stroke severity (NINDS, ECASS-3)
Use of subjective outcome measures (MRS)
Manufacturer involvement in only blinded studies with benefit (NINDS, ECASS-3)
IST-3 - open-label subject to bias with FU calls
Meta-analysis flawed as based on flawed
Controversy over time window - poor correlation in IST-3; apparent window ?more severe strokes likely to present early - 35Pros - tPA in StrokeNNT ~ 11 with persisting benefits in terms of neuro outcomes (at least 3/12)
No increase in mortality overall
Registries suggest safety similar to trials
Supported by many professional societies
Little disruption to ED if additional resources provided by stroke team - 36Cons - tPA in strokeDefinite risk of early ICH and death
2 pos trials suffer from baseline imbalance
2 pos trials - conflicts of interest
Few patient studies (despite mutliple meta-analyses)
Majority of studies show no overall benefit
Systematic rvs based on flawed studies
5% of stroke pts are eligible for lysis
Potential disruption of ED service
NNT likely inflated by pts rx <90 minutes
Difficulty distinguishing stroke mimics
Consent problematic
Stroke prevention and rehab more cost-effective - 37Criteria for tPA in stroke - all must be metNIHSS < 25
CT shows < 1/3 MCA territory
Valid consent able to be obtained
tPA possible within 3 hrs of onset
INR < 1.7
No aspirin and clopidogrel
No NOAC in previous 48 hrs
Information
- Description
- Postgraduate Principles of EM and Medicine Flashcards on Stroke and TIA, created by Natalie Thurtle on 20/04/2015.
- Created by
- Natalie Thurtle
- Views
- 3
- Rating
More on Transient Ischemic Attack